Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Hypoxia Activated Evofosfamide for Treatment of Recurrent Bevacizumab-Refractory Glioblastoma: A phase I surgical study.

Brenner A, Zuniga R, Sun JD, Floyd J, Hart CP, Kroll S, Fichtel L, Cavazos D, Caflisch L, Gruslova A, Lodi A, Tiziani S.

Neuro Oncol. 2018 Feb 5. doi: 10.1093/neuonc/noy015. [Epub ahead of print]

PMID:
29415215
2.

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model.

Hajj C, Russell J, Hart CP, Goodman KA, Lowery MA, Haimovitz-Friedman A, Deasy JO, Humm JL.

Transl Oncol. 2017 Oct;10(5):760-765. doi: 10.1016/j.tranon.2017.06.010. Epub 2017 Jul 31.

3.

Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.

Takakusagi Y, Kishimoto S, Naz S, Matsumoto S, Saito K, Hart CP, Mitchell JB, Krishna MC.

Antioxid Redox Signal. 2018 Jan 10;28(2):131-140. doi: 10.1089/ars.2017.7106. Epub 2017 Sep 8.

PMID:
28741367
5.

Expectations of younger patients concerning activities after knee arthroplasty: are we asking the right questions?

Witjes S, van Geenen RC, Koenraadt KL, van der Hart CP, Blankevoort L, Kerkhoffs GM, Kuijer PP.

Qual Life Res. 2017 Feb;26(2):403-417. doi: 10.1007/s11136-016-1380-9. Epub 2016 Aug 5.

6.

Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.

Duran R, Mirpour S, Pekurovsky V, Ganapathy-Kanniappan S, Brayton CF, Cornish TC, Gorodetski B, Reyes J, Chapiro J, Schernthaner RE, Frangakis C, Lin M, Sun JD, Hart CP, Geschwind JF.

Clin Cancer Res. 2017 Jan 15;23(2):536-548. doi: 10.1158/1078-0432.CCR-16-0725. Epub 2016 Jul 20.

7.

Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.

Yoon C, Chang KK, Lee JH, Tap WD, Hart CP, Simon MC, Yoon SS.

Oncotarget. 2016 Jul 12;7(28):42844-42858. doi: 10.18632/oncotarget.10212.

8.

MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.

Zhang X, Wojtkowiak JW, Martinez GV, Cornnell HH, Hart CP, Baker AF, Gillies R.

PLoS One. 2016 May 26;11(5):e0155289. doi: 10.1371/journal.pone.0155289. eCollection 2016.

9.

Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.

Sun JD, Liu Q, Ahluwalia D, Ferraro DJ, Wang Y, Jung D, Matteucci MD, Hart CP.

Cancer Biol Ther. 2016 Apr 2;17(4):371-80. doi: 10.1080/15384047.2016.1139268. Epub 2016 Jan 28.

10.

Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.

Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE, Bankson JA, Cortes JE, Hart CP, Andreeff M, Konopleva M.

Clin Cancer Res. 2016 Apr 1;22(7):1687-98. doi: 10.1158/1078-0432.CCR-14-3378. Epub 2015 Nov 24.

11.

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

Sun JD, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F, Bhupathi D, Matteucci MD, Hart CP.

Am J Cancer Res. 2015 Jun 15;5(7):2139-55. eCollection 2015.

12.

Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.

Yoon C, Lee HJ, Park DJ, Lee YJ, Tap WD, Eisinger-Mathason TS, Hart CP, Choy E, Simon MC, Yoon SS.

Br J Cancer. 2015 Jun 30;113(1):46-56. doi: 10.1038/bjc.2015.186. Epub 2015 May 26.

13.

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.

Meng F, Bhupathi D, Sun JD, Liu Q, Ahluwalia D, Wang Y, Matteucci MD, Hart CP.

BMC Cancer. 2015 May 21;15:422. doi: 10.1186/s12885-015-1387-6.

14.

TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.

Peeters SG, Zegers CM, Biemans R, Lieuwes NG, van Stiphout RG, Yaromina A, Sun JD, Hart CP, Windhorst AD, van Elmpt W, Dubois LJ, Lambin P.

Clin Cancer Res. 2015 Jul 1;21(13):2984-92. doi: 10.1158/1078-0432.CCR-15-0018. Epub 2015 Mar 24.

15.

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.

Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, Bhupathi D, Ruprell AS, Hart CP.

Cancer Biol Ther. 2015;16(3):438-49. doi: 10.1080/15384047.2014.1003005.

16.

Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.

Bailey KM, Cornnell HH, Ibrahim-Hashim A, Wojtkowiak JW, Hart CP, Zhang X, Leos R, Martinez GV, Baker AF, Gillies RJ.

PLoS One. 2014 Dec 22;9(12):e113586. doi: 10.1371/journal.pone.0113586. eCollection 2014.

17.

Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.

Takakusagi Y, Matsumoto S, Saito K, Matsuo M, Kishimoto S, Wojtkowiak JW, DeGraff W, Kesarwala AH, Choudhuri R, Devasahayam N, Subramanian S, Munasinghe JP, Gillies RJ, Mitchell JB, Hart CP, Krishna MC.

PLoS One. 2014 Sep 25;9(9):e107995. doi: 10.1371/journal.pone.0107995. eCollection 2014.

18.

Intrinsic healing response of the human anterior cruciate ligament: an histological study of reattached ACL remnants.

Nguyen DT, Ramwadhdoebe TH, van der Hart CP, Blankevoort L, Tak PP, van Dijk CN.

J Orthop Res. 2014 Feb;32(2):296-301. Epub 2013 Nov 5.

PMID:
24600702
19.

Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.

Portwood S, Lal D, Hsu YC, Vargas R, Johnson MK, Wetzler M, Hart CP, Wang ES.

Clin Cancer Res. 2013 Dec 1;19(23):6506-19. doi: 10.1158/1078-0432.CCR-13-0674. Epub 2013 Oct 2.

20.

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K.

Mol Cancer Ther. 2013 Sep;12(9):1763-73. doi: 10.1158/1535-7163.MCT-13-0123. Epub 2013 Jul 5. Erratum in: Mol Cancer Ther. 2015 Jul;14(7):1762. De Bryune, Elke [Corrected to De Bruyne, Elke].

21.

Short-term functional outcome after hip resurfacing surgery.

Nijman TH, Scholtes VA, de Meulemeester FR, van der Hart CP, Poolman RW.

Eur J Orthop Surg Traumatol. 2013 Feb;23(2):197-202. doi: 10.1007/s00590-012-0946-7. Epub 2012 Feb 4.

PMID:
23412452
22.

A 30-year-old woman with acute knee injury.

Witjes S, Pels Rijcken TH, van der Hart CP.

Br J Sports Med. 2014 Sep;48(18):1390, 1394-6. doi: 10.1136/bjsports-2012-090952a. Epub 2012 Dec 6. No abstract available.

PMID:
23222194
23.

Guideline on anterior cruciate ligament injury.

Meuffels DE, Poldervaart MT, Diercks RL, Fievez AW, Patt TW, Hart CP, Hammacher ER, Meer Fv, Goedhart EA, Lenssen AF, Muller-Ploeger SB, Pols MA, Saris DB.

Acta Orthop. 2012 Aug;83(4):379-86. doi: 10.3109/17453674.2012.704563. Epub 2012 Aug 20. Review.

24.

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.

Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM.

Blood. 2012 Jun 14;119(24):5782-94. doi: 10.1182/blood-2011-09-380410. Epub 2012 Mar 6.

25.

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1487-98. doi: 10.1007/s00280-012-1852-8. Epub 2012 Mar 2.

26.

Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP.

Clin Cancer Res. 2012 Feb 1;18(3):758-70. doi: 10.1158/1078-0432.CCR-11-1980. Epub 2011 Dec 19.

27.

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP.

Mol Cancer Ther. 2012 Mar;11(3):740-51. doi: 10.1158/1535-7163.MCT-11-0634. Epub 2011 Dec 6.

28.

14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.

Duan JX, Cai X, Meng F, Sun JD, Liu Q, Jung D, Jiao H, Matteucci J, Jung B, Bhupathi D, Ahluwalia D, Huang H, Hart CP, Matteucci M.

J Med Chem. 2011 Mar 24;54(6):1715-23. doi: 10.1021/jm101354u. Epub 2011 Feb 22.

PMID:
21341674
29.

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K.

Blood. 2010 Sep 2;116(9):1524-7. doi: 10.1182/blood-2010-02-269126. Epub 2010 Jun 7.

30.
31.

The occurrence of osteoarthritis at a minimum of ten years after reconstruction of the anterior cruciate ligament.

van der Hart CP, van den Bekerom MP, Patt TW.

J Orthop Surg Res. 2008 Jun 10;3:24. doi: 10.1186/1749-799X-3-24.

32.

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M.

J Med Chem. 2008 Apr 24;51(8):2412-20. doi: 10.1021/jm701028q. Epub 2008 Feb 8.

PMID:
18257544
33.

A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.

Meng F, Cai X, Duan J, Matteucci MG, Hart CP.

Cancer Chemother Pharmacol. 2008 May;61(6):953-63. Epub 2007 Jul 18.

PMID:
17639393
34.

ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation.

Meng F, Nguyen XT, Cai X, Duan J, Matteucci M, Hart CP.

Anticancer Drugs. 2007 Apr;18(4):435-45.

PMID:
17351396
35.

Mid-term results of arthroscopic reconstruction in chronic posterior cruciate ligament instability.

Jenner JM, van der Hart CP, Willems WJ.

Knee Surg Sports Traumatol Arthrosc. 2006 Sep;14(9):848-53. Epub 2006 Apr 8.

PMID:
16604359
36.

Finding the target after screening the phenotype.

Hart CP.

Drug Discov Today. 2005 Apr 1;10(7):513-9. Review.

PMID:
15809197
37.

Changes in bone scans after anterior cruciate ligament reconstruction: a prospective study.

Hogervorst T, Pels Rijcken TH, Rucker D, van der Hart CP, Taconis WK.

Am J Sports Med. 2002 Nov-Dec;30(6):823-33.

PMID:
12435648
38.

Abnormal bone scans of the tibial tunnel 2 years after patella ligament anterior cruciate ligament reconstruction: correlation with tunnel enlargement and tibial graft length.

Hogervorst T, van der Hart CP, Pels Rijcken TH, Taconis WK.

Knee Surg Sports Traumatol Arthrosc. 2000;8(6):322-8.

PMID:
11147149
39.

Abnormal bone scans in anterior cruciate ligament deficiency indicate structural and functional abnormalities.

Hogervorst T, Pels Rijcken TH, van der Hart CP, De Lange ES, Taconis WK.

Knee Surg Sports Traumatol Arthrosc. 2000;8(3):137-42. Erratum in: Knee Surg Sports Traumatol Arthrosc 2000;8(6):373.

PMID:
10883423
40.

Selection of estrogen receptor beta- and thyroid hormone receptor beta-specific coactivator-mimetic peptides using recombinant peptide libraries.

Northrop JP, Nguyen D, Piplani S, Olivan SE, Kwan ST, Go NF, Hart CP, Schatz PJ.

Mol Endocrinol. 2000 May;14(5):605-22.

PMID:
10809226
41.

Potent inhibitory ligands of the GRB2 SH2 domain from recombinant peptide libraries.

Hart CP, Martin JE, Reed MA, Keval AA, Pustelnik MJ, Northrop JP, Patel DV, Grove JR.

Cell Signal. 1999 Jun;11(6):453-64.

PMID:
10400318
42.

Genetic recombination as a reporter for screening steroid receptor agonists and antagonists.

Dias JM, Go NF, Hart CP, Mattheakis LC.

Anal Biochem. 1998 Apr 10;258(1):96-102.

PMID:
9527854
43.
44.

Homeotic transformation of the occipital bones of the skull by ectopic expression of a homeobox gene.

Lufkin T, Mark M, Hart CP, Dollé P, LeMeur M, Chambon P.

Nature. 1992 Oct 29;359(6398):835-41.

PMID:
1359423
45.

Genetic linkage analysis of the murine developmental mutant velvet coat (Ve) and the distal chromosome 15 developmental genes Hox-3.1, Rar-g, Wnt-1, and Krt-2.

Hart CP, Compton JG, Langley SH, Hunihan L, LeClair KP, Zelent A, Roderick TH, Ruddle FH.

J Exp Zool. 1992 Aug 1;263(1):83-95.

PMID:
1379621
46.

The developmental expression pattern of a new murine homeo box gene: Hox-2.5.

Bogarad LD, Utset MF, Awgulewitsch A, Miki T, Hart CP, Ruddle FH.

Dev Biol. 1989 Jun;133(2):537-49.

PMID:
2567250
47.

The Hox-2 homeo box gene complex on mouse chromosome 11 is closely linked to Re.

Hart CP, Dalton DK, Nichols L, Hunihan L, Roderick TH, Langley SH, Taylor BA, Ruddle FH.

Genetics. 1988 Feb;118(2):319-27.

48.
49.

Polypurine/polypyrimidine sequence elements of the murine homeo box loci, Hox-1, -2 and -3.

Hart CP, Bogarad LD, Fainsod A, Ruddle FH.

Nucleic Acids Res. 1987 Jul 10;15(13):5495. No abstract available.

50.

Homeo box genes in murine development.

Fienberg AA, Utset MF, Bogarad LD, Hart CP, Awgulewitsch A, Ferguson-Smith A, Fainsod A, Rabin M, Ruddle FH.

Curr Top Dev Biol. 1987;23:233-56. Review.

PMID:
2897895

Supplemental Content

Support Center